Highlights of Prescribing Information: Wegovy (semaglutide) injection, for subcutaneous use Wegovy (semaglutide) tablets, for oral use
Effect of exenatide after short-time intensive insulin therapy on glycaemic remission maintenance in type 2 diabetes patients: a randomized controlled trial
The adequate management of GI AEs would potentially improve a patients experience while undergoing treatment with GLP-1 RA, preventing discontinuations secondary to GI AEs
Back House Resolution HR1147 Congratulations to Dr Graeme Bell
The glucagon receptor agonism, whilst counterintuitive given glucagon's role in raising blood glucose, is thought to increase energy expenditure and promote hepatic fat oxidation whilst reducing lipogenesis effects that may offer potential benefits in metabolic dysfunction-associated steatotic liver disease (MASLD)
Semaglutide replicates these effects, helping individuals consume fewer calories, which can be particularly beneficial for those looking to lose weight as part of a broader aesthetic or health-related goal